MX9701857A - Aminoalquil-eteres y acilaminoalquil-eteres, procedimiento para su preparacion y su utilizacion como antagonistas de receptores de bradiquinina. - Google Patents

Aminoalquil-eteres y acilaminoalquil-eteres, procedimiento para su preparacion y su utilizacion como antagonistas de receptores de bradiquinina.

Info

Publication number
MX9701857A
MX9701857A MX9701857A MX9701857A MX9701857A MX 9701857 A MX9701857 A MX 9701857A MX 9701857 A MX9701857 A MX 9701857A MX 9701857 A MX9701857 A MX 9701857A MX 9701857 A MX9701857 A MX 9701857A
Authority
MX
Mexico
Prior art keywords
acylaminoalkyl
ethers
esters
aminoalkyl
bradiquinine
Prior art date
Application number
MX9701857A
Other languages
English (en)
Other versions
MXPA97001857A (es
Inventor
Holger Heitsch
Adalbert Wagner
Klaus Wirth
Bernward Scholkens
Gerhard Nolken
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MX9701857A publication Critical patent/MX9701857A/es
Publication of MXPA97001857A publication Critical patent/MXPA97001857A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

Se describen aminoalquil-éteres y acilaminoalquil-éteres, que se distinguen por una alta afinidad para el receptor B2 de bradiquinina y por una solubilidad mejorada en agua. Estos aminoalquil-éteres y acilaminoalquil-éteres se pueden representar por la formula general (I): (Ver Formula) en la que R1, R2, R3 significan alquilo, arilo, alquilarilo, halogeno, hidrogeno, cicloalquilo, CHO, CO-O-alquilo, COOH; R4, R5 significan hidrogeno, halogeno, alcoxi, nitro, ciano, S-alquilo; n significa un numero de 1 a 8; R6 significa hidrogeno, alquilo, alquilalquenilo, alquilarilo; R7 significa hidrogeno y un radical acilo sustituido o sin sustituir. También se describe un procedimiento para la preparacion de los componentes de la formula (I).
MXPA/A/1997/001857A 1996-03-13 1997-03-12 Aminoalquil-eteres y acilaminoalquil-eteres, procedimiento para su preparacion y su utilizacion como antagonistas de receptores de bradiquinina MXPA97001857A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19609827A DE19609827A1 (de) 1996-03-13 1996-03-13 Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19609827.0 1996-03-13

Publications (2)

Publication Number Publication Date
MX9701857A true MX9701857A (es) 1997-09-30
MXPA97001857A MXPA97001857A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
HRP970138A2 (en) 1998-04-30
KR970065521A (ko) 1997-10-13
DE19609827A1 (de) 1997-09-18
TR199700184A2 (xx) 1997-10-21
ATE192738T1 (de) 2000-05-15
SI0795547T1 (en) 2000-10-31
ID16217A (id) 1997-09-11
HUP9700566A1 (hu) 2000-08-28
AR006189A1 (es) 1999-08-11
CA2199771A1 (en) 1997-09-13
PL318923A1 (en) 1997-09-15
BR9701267A (pt) 1999-01-12
JPH101472A (ja) 1998-01-06
NO971136L (no) 1997-09-15
IL120427A0 (en) 1997-07-13
DE59701617D1 (de) 2000-06-15
NO971136D0 (no) 1997-03-12
DK0795547T3 (da) 2000-09-18
EP0795547B1 (de) 2000-05-10
GR3033415T3 (en) 2000-09-29
AU1621797A (en) 1997-09-18
ES2148858T3 (es) 2000-10-16
PT795547E (pt) 2000-10-31
HU9700566D0 (en) 1997-04-28
CZ76697A3 (en) 1997-10-15
SK32097A3 (en) 1998-01-14
JP4317597B2 (ja) 2009-08-19
EP0795547A1 (de) 1997-09-17
TW363891B (en) 1999-07-11
US6140341A (en) 2000-10-31
ZA972129B (en) 1997-09-15

Similar Documents

Publication Publication Date Title
HUP0000079A2 (hu) Indán- és dihidroindolszármazékok
ATE175198T1 (de) N-acylierte trizyklische azaheteroringe verwendbar als vasopressin-antagonisten
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
NO20015226D0 (no) Tri-aryl syrederivater som PPAR reseptor ligander
PL334084A1 (en) Methods of obtaining 9,11-epoxysteroides and their useful intermediate compounds
PL323666A1 (en) Semicarbasones acting on central nervous system and pharmaceutic agents containing them
TR199700184A2 (xx) Aminoalkil ve asilaminoalkil eterleri, bunlar�n �retilmesine mahsus usul ve bradikinin resept�r antagonistleri olarak kullan�lmalar�.
EA200000336A1 (ru) Антагонисты рецептора витронектина
MY113266A (en) New indol derivatives derivatives with high affinity 5-ht1a receptor.
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
EA200200727A1 (ru) Новые производные индола
AP9801410A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists.
DK0779895T3 (da) Forbedret fremgangsmåde til fremstilling af sidekædederivater af cyclohexapeptidyl-lipopeptider
GB2341799B (en) Medicaments for the treatment of primary headache disorders and drug-induced headaches
DK0613896T3 (da) Fremgangsmåde til fremstilling af sulfonylurinstofderivater
MY130817A (en) Herbicides
YU51599A (sh) POSTUPAK I INTERMEDIJERI ZA β3-ADRENERGIČNI RECEPTORSKI AGONIST
DK0630893T3 (da) N,N'-disubstitueret amidderivat
DE69316392D1 (de) Azanoradamantane
ES2170802T3 (es) Carboxamidas biciclicas como ligandos de los receptores 5-ht1a.
MX9702028A (es) Antagonistas de bradiquinina heterociclicos, sustituidos con fluoroalquilo y fluoroalcoxi, procedimientos para su preparacion y su utilizacion.
CO4920233A1 (es) Acidos aminobutiricos gamma substituidos como agentes farmaceuticos